Danaher Corporation $DHR Stock Sold by AMF Tjanstepension AB

Key Points

• AMF Tjanstepension AB cut its Danaher stake by 49.3% in the third quarter, selling 174,440 shares and retaining 179,251 shares valued at approximately $39.7 million. Institutional investors collectively own about 79.1% of Danaher.
• Danaher reported third-quarter adjusted EPS of $2.11, beating the $1.92 consensus estimate, while revenue rose 8.3% year over year to $6.55 billion. Management raised its 2026 adjusted EPS outlook to $8.57–$8.62, citing stronger biotechnology demand and margin improvement.
• Analysts generally remain bullish, with several raising price targets to $270–$275 and the stock carrying a consensus “Moderate Buy” rating. However, tariff pressure, a cautious 2027 outlook and a relatively high valuation could limit further gains.

AMF Tjanstepension AB decreased its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 49.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 179,251 shares of the conglomerate's stock after selling 174,440 shares during the quarter. AMF Tjanstepension AB's holdings in Danaher were worth $39,713,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DHR. Lmcg Investments LLC lifted its position in shares of Danaher by 1.3% in the 3rd quarter. Lmcg Investments LLC now owns 126,026 shares of the conglomerate's stock worth $27,921,000 after acquiring an additional 1,599 shares during the period. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in shares of Danaher during the 3rd quarter worth approximately $997,000. Canoe Financial LP increased its position in shares of Danaher by 43.3% during the third quarter. Canoe Financial LP now owns 800,124 shares of the conglomerate's stock valued at $169,434,000 after purchasing an additional 241,910 shares during the period. Strengthening Families & Communities LLC raised its stake in shares of Danaher by 3.4% in the third quarter. Strengthening Families & Communities LLC now owns 3,638 shares of the conglomerate's stock valued at $806,000 after purchasing an additional 121 shares in the last quarter. Finally, Atticus Wealth Management LLC acquired a new position in shares of Danaher in the third quarter valued at $221,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, ahead of the $1.92 analyst consensus, while revenue increased 8.3% year over year to $6.55 billion. Biotechnology profitability and improving demand across several end markets supported the earnings beat. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: Management raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, and biotechnology orders grew at a mid-teens rate. The company also highlighted margin expansion, improving customer demand, and artificial-intelligence capabilities that could support longer-term drug-discovery growth. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Several analysts raised their price targets, including TD Cowen and JPMorgan to $270, Goldman Sachs to $275, and Stifel to $260. The upgrades reflect confidence in the earnings beat, improved execution, and the stronger profit outlook.
• Neutral Sentiment: New CEO Julie Montgomery emphasized the need to improve execution and innovation. Investors are watching whether management can convert the company’s AI and biotechnology investments into sustained growth. Danaher Posts First Earnings Under New CEO
• Negative Sentiment: Revenue was approximately in line with, or slightly below, estimates, while analysts cited tariff pressure and a cautious 2027 outlook. At roughly 41 times earnings, Danaher’s valuation leaves limited room for operational disappointment, contributing to the negative investor reaction despite the quarterly beat.

Danaher Stock Performance

Danaher stock opened at $229.86 on Friday. The firm has a market capitalization of $161.59 billion, a P/E ratio of 28.04, a P/E/G ratio of 2.95 and a beta of 0.76. The stock has a fifty day moving average price of $215.76 and a two-hundred day moving average price of $197.12. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating the consensus estimate of $1.92 by $0.19. The company had revenue of $6.55 billion for the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a net margin of 16.91% and a return on equity of 11.22%. The firm's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.89 EPS. As a group, analysts anticipate that Danaher Corporation will post 8.51 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher's payout ratio is 28.42%.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Royal Bank Of Canada raised their target price on Danaher from $215.00 to $250.00 and gave the stock an "outperform" rating in a research report on Monday, October 5th. Wall Street Zen lowered shares of Danaher from a "buy" rating to a "hold" rating in a report on Sunday, October 18th. TD Cowen increased their price objective on shares of Danaher from $255.00 to $270.00 and gave the company a "buy" rating in a research note on Thursday. The Goldman Sachs Group reaffirmed a "buy" rating and set a $275.00 price objective on shares of Danaher in a report on Thursday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Danaher from $250.00 to $270.00 and gave the company an "overweight" rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $242.91.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.